US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
RSS Feeds

Biotechnology market research reports and industry analysis

1  2  3    5    7  8  9  10  
Alkermes Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... you require to better understand Alkermes and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal ...  |  read more...
USD 995
Amgen Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying ...  |  read more...
USD 995
Anika Therapeutics Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... the information you require to better understand Anika Therapeutics and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up ...  |  read more...
USD 995
Biogen Idec Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding ...  |  read more...
USD 995
Celgene Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying ...  |  read more...
USD 995
Dendreon Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... you require to better understand Dendreon and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal ...  |  read more...
USD 995
Genentech Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying ...  |  read more...
USD 995
Genmab Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... you require to better understand Genmab and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal ...  |  read more...
USD 995
Genzyme Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying ...  |  read more...
USD 995
Intermune Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... you require to better understand Intermune and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal ...  |  read more...
USD 995
Nektar Therapeutics Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... the information you require to better understand Nektar Therapeutics and its partnering interests and activities over the past seven years. On demand company reports are prepared upon purchase to ensure inclusion of the most up ...  |  read more...
USD 995
Novartis Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... require to better understand Novartis and its partnering interests and activities over the past five years. On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and ...  |  read more...
USD 995
Genetic Disorders Partnering Terms and Agreements
8/1/2014 | published by: Current Partnering
... are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. ...  |  read more...
USD 1,995
Marketed Stage Deals and Alliances of 2013
8/1/2014 | published by: Current Partnering
... healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals ...  |  read more...
USD 1,495
Clinical Stage Deals and Alliances of 2013
8/1/2014 | published by: Current Partnering
... healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals ...  |  read more...
USD 1,495
Discovery Stage Deals and Alliances of 2013
8/1/2014 | published by: Current Partnering
... healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals ...  |  read more...
USD 1,495
Public Health Deals and Alliances of 2013
8/1/2014 | published by: Current Partnering
... healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals ...  |  read more...
USD 1,495
Proteins in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 667 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 190 drugs. Proteins In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
Cesca Therapeutics Inc. (KOOL) - Financial and Strategic SWOT Analysis Review
7/15/2014 | published by: GlobalData
... you a clear and an unbiased view of the company‚Äôs key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ...  |  read more...
USD 125
Personalized Medicine in Oncology Partnering Terms and Agreements
8/1/2014 | published by: Current Partnering
... by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the ...  |  read more...
USD 2,995
Monoclonal Antibodies Partnering Terms and Agreements
8/1/2014 | published by: Current Partnering
... obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest ...  |  read more...
USD 2,995
DNA Vaccines: Technologies and Global Markets
7/1/2014 | published by: BCC Research
... by 2019, a compound annual growth rate (CAGR) of 54.8% over the five-year period from 2014 through 2019. This report provides: An overview of the global market for DNA vaccines and related technologies. Analyses of ...  |  read more...
USD 6,650
Blood-Brain Barrier Technologies and Global Markets
7/1/2014 | published by: BCC Research
... million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019. This report provides: An overview of the global market for blood-brain barrier (BBB) therapeutics and technologies. Analyses of global market ...  |  read more...
USD 6,650
Charles River Systems, Inc.
6/26/2014 | published by: SGA ExecutiveTracker
... City, State & Zip), US HQ Phone Number & Company Website Address, Ticker Symbol, Most Recent Revenues Reported, Number of Employees and Industry. SGA Business Lists do not include direct-dial phone numbers for all executives ...  |  read more...
USD 25
ImmunoGen, Inc.
6/26/2014 | published by: SGA ExecutiveTracker
... City, State & Zip), US HQ Phone Number & Company Website Address, Ticker Symbol, Most Recent Revenues Reported, Number of Employees and Industry. SGA Business Lists do not include direct-dial phone numbers for all executives ...  |  read more...
USD 30
1  2  3    5    7  8  9  10